Burgdorf/San Diego – Ypsomed (SWX:YPSN) and DexCom Inc. (NASDAQ:DXCM), the world's leading provider of continuous glucose monitoring (CGM) systems, announce their partnership to drive development of a hybrid closed loop system. The partnership is an important milestone in the further development of individualised diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife App from Ypsomed.

Individualisation in diabetes therapy

mylife Stories

The number of Type 1 diabetics using old insulin pumps without secure communication interfaces to build their own “Closed Loop” system is growing steadily. The so-called “loopers” are thus sending a clear signal to manufacturers and showing what is in demand for insulin pump therapy.